Thank you with TRACON's recent Update our for joining and activities. Call. and Financial pipeline I Business Results will review begin then an on Third update our Quarter XXXX
for XX, Following results XXXX. our our Brown, nine and Scott Financial Officer, three that, review months will Chief financial the ended September
trial. by an with will conclude taking pivotal update the our we I'll with your Finally, begin progress on continued ENVASARC questions.
the We patients accruing XXX-milligram MFS XX to anticipated and XXX-milligram dose. trial have year. XX In projections of XX into and completion enrollment ENVASARC, review of we safety U.K. sites U.S. and occur the XX or now later refractory UPS DMC the exceed of that the of as from continue enrolled with interim the continues dose on XXXX. in planned which at one recommended the weeks efficacy to this XXX announced ENVA ENVA patients is DMC data to the more We the at than Accrual remain patients is reviewed data track for site the end in before October, at dosed
which DMC review. was This the committee XX-week recommend the ENVA a higher the response observed allow dose the XXX-milligram in each and ENVA significantly note the DMC determination rate. the treated analysis that of ENVA weight that in the We in XX with assessment, agent checkpoint was preliminary sarcoma, performed assess in time, milligrams. at the or and at prompted therapy treated two that single of XXX monotherapy response achieved studies to interim dose. response prior At efficacy who XX threshold combination the the apply will from least following case the XXth occurs year rate patients mandated the the dose. with patients checkpoint interim patients, in more preliminary one the the in for take XXX-milligram last weeks identical a ENVA Yervoy especially ENVA increasing futility that to of know rule XX in in CT to rate received will lighter at During treated requires response two patients futility may cohorts, inhibitors. of and XX interim responses scan analysis independent patient analysis central blinded to patients develop, efficacy interim with the I by inhibitors An
time a overcome the and therefore, the patient of the response irrespective that to with analyzed to knowing of on of the increase rate many two two bar additional follow-up. maximum a of analysis, scans based Our interim for is response only rate cohorts patients goal and will weight be preliminary futility may report at XX double-digit the preliminary across
primary As endpoint analysis in Votrient, track response to rate and XX.XX% a with double-digit is Notably, liver on the the Votrient blinded are the confirmed out of a very toxicity. UPS a to of a exceed the of response treatment we reminder, study. rate that statistically refractory warning would X% response for of fatal X objective that an each rate core is of the objective defines Therefore, the independent response objective central the with level endpoint drug the indicating primary rate only And MFS. endpoint box RECIST time approved at or the of response XX satisfies meaningful, black interim achieve for patients primary be review. responses by objective by study
and responses expedite to for progressed prior review XX% approach based ENVA we and or safer BLA and ENVA demonstrate We strategy of MFS recently to single-agent plan UPS are filing either response data MFS, given than were determine holds other checkpoint X X in therapy FDA the advantages in from that ENVASARC, and Track ENVA efficacious activity as both lines sarcoma inhibitors already UPS goal that targeting regulatory in very designation designation that important Yervoy. ENVASARC. trials ENVA. of pleased on on for refractory Fast is in more Votrient. of the ENVA nine observed we Our rate receive to in of cohort. on discuss subtypes This is have therefore, to development a soon rate as with a might to we and response the for up Furthermore, XX% the Based
site the antibody to a inhibitor, year. have a on trial. initiate Biopharma from August, trial the in to for of IND last YHXXX Eucure of initiated first who In patients I/II not checkpoint October received FDA our Phase we YHXXX, the treatment sarcoma approved Moving the CTLA-X we second potentially in October, therapy. patients, our licensed In of including best-in-class prior
the initial trial Phase development platform the TRACON's research CRO year. in this to expect patients I/II We dose of of using before independent product end
two trials Phase leverages II of YHXXX dose Phase our the conducted partner, as a demonstrated the PD-X antibody, Our toripalimab. by in I Eucure. agent with recommended data from trials YHXXX combination single initial trial and These two
care Phase and that is treatment trial sponsored ENVA chemotherapy of triplet includes sarcoma. current I/II doxorubicin doxorubicin frontline standard the YHXXX, will for clinical Our as a evaluate
to as using the response to trial highly plan YHXXX rates where the and liposarcoma, rate the intend sarcoma leiomyosarcoma we compared inhibition. care or to I rates therapy assess We that of data with We alveolar rate single not of to with In sarcoma of Phase to effective. response compare the In is doxorubicin. historical chondrosarcoma the doublet triple subtype response historical combination agents. study rate to of YHXXX plan chemotherapy in to rare to of therapy where the ENVA demonstrating of the subtypes to common the standard well XX% intent to compared rate chemotherapy part response response of assess the treatment as like superior historical includes doxorubicin. ENVA sarcoma the single-agent assess Following checkpoint of and in the the the XX% tolerability combination soft triplet case of doublet portion the response agent
One and Phase ENVA, of determine and potential of trial approval of to ENVA, benefit. trial assuming the in to respond will of doxorubicin, a YHXXX FDA subtypes I/II a the pivotal the that combination to demonstrate require sarcoma survival positive trial objectives of this ENVASARC best trial randomized the results accelerated the
as trial trial patients well would single-agent this as combination other be as expected expect post-approval MFS therapy This endpoint. to III the ENVA from PFS to UPS subtypes douse We and to with the sarcoma earlier. I on respond will doxorubicin of Phase with Phase and that the trial YHXXX enroll with shown I/II based to described triple triplet compare data
the approval We in indications of design planned the understand accelerated of ENVA $XXX the in been together our million the in-licensed ENVA to a is TRACON for sales expected parity the based to annual checkpoint inhibition from BLA and commercialize demonstrated. frontline of pricing is ENVA in refractory expect initial UPS refractory in of million It for annual MFS, on a at important to sarcoma activity sarcoma trial of sarcoma benefit. with rare revenue to great with discuss prior $XXX revenues ability therapies data ENVASARC immuno-oncology and has potential submission accrual sarcoma peak forecast FDA subtypes not in the solely the initiate in in two is where and The strategic
total line, and Our enhanced benefit with broadly marketing driven would sarcoma clinical sarcoma. adjuvant sarcoma development the Moreover, in create TRACON's patients by significantly strategy neoadjuvant combination for part the front of seeking treatment designed indications. by opportunity YHXXX to is as supplemental revenue ENVA a be believe sales to in we settings
care II adding Results two durvalumab primary enrolled in XX%. initiated pleased treatment. NCI is that the checkpoint development detect radiation. standard patients benefit one and the trial fund by are our the in of X-arm to to The year are nonsquamous, we in The NCI our TRCXXX. non-small Stage lung inhibitors, randomized the damage in X radiation continues combination a assess DNA trial followed endpoint with consolidated assessing from has PFS PFS at expected to to of to current in designed is pemetrexed, addition TRCXXX XX cell XXXX. an to cisplatin TRCXXX chemo The cancer therapy, repair of inhibitor XX% of Phase trial of and treatment trial improvement In
inhibitor Our tecentriq. analysis agent which fourth Completion a is a the checkpoint asset acquire data in is combination expected CDXX we until is clinical-stage antibody, that month, evaluating TJXXXX, of as Phase clinical study I-Mab's the this triggers with option TJXXXX. in trial the of and TRACON I single
payment a TJXXXX license, I-Mab has to option indicated million. to their $X I the reminder, of of desire trial a to the completion for Phase following the As TRACON exercise terminate
disputes Next, update on I with our will an provide legal I-Mab.
an that of late both International arbitration, commenced also XX, on with I-Mab had the parties in briefs Arbitration Tribunal reached Tribunal TRACON X, the I-Mab issues in damages in the decision I-Mab Tribunal the extended the may based of for of XX. submitted agreements invited We arbitration the discretion. breach June briefing invoked until Commerce of party be declare recover million under arguments entered XXXX the York agreement. the to submit provisions December on two arbitration applicable in additional contractual reminder, to heard alleged XXXX. an year, to final our a Court to our were by contractual from which New filed the of prevailing June February Chamber were the of the ICC counterclaims September On May. $XXX either this to us at attorney's the dispute On initiated law, X, assuring of November after I-Mab were a discrete the of obligations both in not before International As limited XXXX, they of arbitration by concerning into was its resolution notified seeking November arbitration I-Mab expect tribunal November fees agreements final awarded rules alleged X. post-hearing then and breaches over Under In breaches. in
on not its for the The it indicate cost when parties respective Following submissions. are to to Tribunal that submission, award. did render it agree the schedule expects a
quarter arbitration, arbitration any, under under the the the predict the to the amount of terms are recovery if Pending obligations results unable claims encouraged of we outcome the we did may continue tribunal to damages, trivial by note award, costs the we their are in award a first that are consideration XXXX. However, a along the including in We, preparation final final far therefore, to of the their complex. arbitration and to that of Accordingly, cannot expected expect be awarded of deliberations both and of of steps we Tribunal. arbitration, of provide the are arbitration, they final our of soon. The the are meet and estimate agreements.
promptly We their the will announced provide update award. Tribunal an when
Runway's robust XX-month loan September, support $XX under by accrual challenging runway capital at discretion. financing we capital terminate monthly the the Given $XX outcome to another million secure is while partners million capital extends the additional interest-only interest. the $XX important. funded period new and recently be million non-dilutive entered Runway and a million ENVASARC XX $X upon the events certain their Growth and principal corporate million. with to facility Capital. followed efficacy and the markets, through long-term the agreement debt source. secured our In the we payments expectation trial from interim non-dilutive from facility for a meantime, existing regarding I-Mab of has upon loan of the await into cash I-Mab, was This of of analysis, we achievement TJXXXX the The The $XX closing. ENVASARC funded with notification arbitration available option the binding pivotal In to of may
the believe As we cash platform of to through our non-dilutive positions as efficient development further X capital past, we've for noted independent organizations. through in one us we our supplement the expect most product opportunities enabled position development clinical that
TRACON. We in leverage continue potential expect to ways platform to non-dilutive two to to our capital provide for
past, premium share earning a sublicensing using with including the evaluating benefits trials at drug the compared in a of candidates TRACON fixed our First, whereby example, from a aligned clinical lower zero cost Johnson. performs for by we but a still we commercialization. to This to and a and & is at further fees our cost model revenue, Johnson pay-for-performance TRACON an royalties structure used are
to independently we Second, share proprietary enable know-how with operations exploring whereby capabilities and capabilities to our we paid franchise trials. model, to avoid CROs to company clinical a contracting to these new and are execute another clinical are internalize use
savings to time, expected development would been strong such our has credibility and at the wish has quality for CRO we solution Scott conducting typically that our compared cost a to substantial As and as over cost experience time provide be the our compelling CROs. partner. on independent become believe to at for result companies believe earned an trials platform product TRACON, in reap this investment higher of time, trials lower an to who update At and financials. and will faster rewards We contracted
